Wen Fang

HaploX Investment Holding Ltd. engages in the provision of genetic testing solutions with a focus on using molecular diagnostics technologies. It offers genetic testing results that enable full cycle health management for cancer and other patients as well as health screening and risk assessment for individuals, genetic testing of pathogenic microbes, and other pathogens, to research and development genetic testing primarily for biopharmaceutical companies and research institutes. The company was founded by Ming Yan Xu, Yuan Wen, Shi Fu Chen, and Wen Fang on November 29, 2021 and is headquartered in Hong Kong.

Shenzhen Haplox Biotechnology Co. Ltd. develops clinical application device which helps to detect cancer tumour. The firm’s products cover cancer early screening, individualized drug guidance, prognosis monitoring, drug resistance assessment and provide precision cancer health care for the patients. The company was founded by Shi Fu Chen, Wen Fang, Yuan Wen and Ming Yan Xu on September 12, 2014 and is headquartered in Shenzhen, China.